LivaNova’s “D” rating from TheStreet indicates company’s struggles

Trending News 🌧️

Livanova Plc Intrinsic Value – LIVANOVA ($NASDAQ:LIVN): LivaNova PLC is a medical technology company that develops and commercializes products for the treatment of cardiovascular diseases and neurological disorders. The company’s product portfolio includes implantable cardioverter defibrillators, pacemakers, heart valves, and neurostimulation devices. LivaNova’s “D” rating from TheStreet reflects the company’s challenges. LivaNova is facing increased competition from larger medical technology companies such as Medtronic and Boston Scientific . In addition, LivaNova has been hit by tariffs on its products imported from China.

However, TheStreet’s rating reflects the company’s challenges in achieving this growth. LivaNova will need to drive strong sales of its new products, including its recently launched cardiac monitoring system, to meet its targets.

Market Price

LivaNova PLC , a medical technology company, has been struggling as of late. TheStreet has given the company a “D” rating, indicating that the media coverage surrounding the company is mostly negative. On Friday, LIVANOVA PLC stock opened at $45.9 and closed at $45.7. This indicates that investors are not confident in the company’s future.

VI Analysis – Livanova Plc Intrinsic Value

The company’s products include implantable cardioverter defibrillators, pacemakers, and heart valves. The company’s fundamentals reflect its long term potential. The fair value of LIVANOVA PLC share is around $67.0, calculated by VI Line. Now LIVANOVA PLC stock is traded at $45.7, undervalued by 32%.

VI Peers

The company’s products include implantable cardioverter defibrillators, pacemakers, percutaneous transluminal coronary angioplasty catheters, stents, and thrombectomy devices. LivaNova PLC operates in Europe, the United States, Asia Pacific, the Middle East, and Africa. The company was formerly known as Sorin Group S.p.A. and changed its name to LivaNova PLC in February 2016. LivaNova PLC was founded in 1956 and is headquartered in London, the United Kingdom. LivaNova PLC‘s competitors include MicroPort Scientific Corp, Fukuda Denshi Co Ltd, and PetVivo Holdings Inc.

– MicroPort Scientific Corp ($SEHK:00853)

MicroPort Scientific Corp is a medical device company that develops, manufactures, and markets a broad range of products and solutions for the treatment of cardiovascular diseases. The company has a market cap of 31.83B as of 2022 and a return on equity of -19.11%. MicroPort’s products and solutions are used in a variety of procedures, including coronary angioplasty, stenting, and valve replacement. The company’s products are sold in over 50 countries worldwide.

– Fukuda Denshi Co Ltd ($TSE:6960)

With a market cap of 114.93B as of 2022, Fukuda Denshi Co Ltd is one of the largest companies in Japan. The company produces a wide range of products, including medical equipment, electronic products, and communications equipment. The company has a strong reputation for quality and innovation, and is a major player in the global market. Fukuda Denshi Co Ltd has a return on equity of 9.95%, which is relatively high for a large company. The company’s strong financial performance is due in part to its efficient operations and sound management.

– PetVivo Holdings Inc ($NASDAQ:PETV)

PetVivo Holdings Inc is a pet health and wellness company that focuses on the development and commercialization of pet health products. The company has a market capitalization of $25.78 million and a return on equity of -79.79%. The company’s products include a line of CBD-based pet health products, as well as a line of pet supplements.

Summary

If you’re looking for a healthcare stock that’s been beaten down and could be ripe for a turnaround, LIVANOVA PLC might be worth a closer look. The company has struggled in recent years, and its stock has taken a beating.

However, LIVANOVA does have some significant positives working in its favor. For one, the company is a leader in cardiac rhythm management devices. This is a growing market, and LIVANOVA is well-positioned to benefit from it. The company also has a strong presence in neuromodulation, another promising healthcare market. This could be a game-changer for the company, and it’s something that investors should keep an eye on. Of course, there are risks to consider with LIVANOVA as well. The company is still working to integrate Cyberonics, and there’s no guarantee that the acquisition will pay off.

Additionally, LIVANOVA faces significant competition in both the CRM and neuromodulation markets. Investors should do their own due diligence before considering an investment in the company.